Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
MultiCell Technologies Inc (EM)
MCET
Healthcare
Biotechnology
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a...
preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc....
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (EXPM:MCET)
New Post
View:
Posts & Comments
Threaded Posts
(0)
•••
MCETDREAMER
X
Post by
MCETDREAMER
on Jun 30, 2021 7:34pm
It is incomprehensible that MCET management refuses to file
It is incomprehensible that MCET management refuses to file with the SEC. It's ludicrous, that over 10 companies, one of which has 18 distributors around the world using MCETs Fa N2-4 patented
...more
(0)
•••
MCETDREAMER
X
Post by
MCETDREAMER
on Jun 29, 2021 10:05pm
Sekisui XenoTech is Infringing on MCET Fa N2-4 Patent
Sekisui XenoTech Global Distribution Network has 18 distributors around the world illegally using the Fa N2-4 Immortalized human hepatocytes cell lines patent without paying a dime to Multicell
...more
(0)
•••
MCETDREAMER
X
Post by
MCETDREAMER
on Jun 29, 2021 10:01pm
Corporations Infringing on Multicell Technology Inc.
There are more Corporations Infringing on the Fa N2-4 immortalized Human Hepatocytes Cell Lines. This information doesn't include any of the MCT family of drugs lines. This also should get
...more
(0)
•••
MCETDREAMER
X
Post by
MCETDREAMER
on Jun 29, 2021 10:00pm
The latest company infringing on MCETs patent to come to the
Clonetech, Takara bio new to the market as of 2-26-2021 TAKAERA BIO WEBSITE: What's new Takara Bio USA, Inc. elevates the sensitivity of scRNA-seq in its continuing mission to support the efforts
...more
(0)
•••
MCETDREAMER
X
Post by
MCETDREAMER
on Jun 29, 2021 9:54pm
Multicell Technology inc Pre-Phase one potential lawsuit
Multicell Technology inc Pre-Phase one potential lawsuit. This is an exploratory investigation for a potential lawsuit to see if there are enough interested investors to support a lawsuit for neglect
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
Vertical integration could reshape this scaling beverage brand’s long-term outlook
A transformational year in 2025 and positive outlook for growth in revenue and profitability in 2026
A custom portable drill advancing exploration in Labrador
A clean tech company on the verge of transformational growth plans to uplist to major US exchange
Podcasts